SMT201400029B - Terapia di disturbi neurologici a base di baclofene e acamprosato - Google Patents

Terapia di disturbi neurologici a base di baclofene e acamprosato

Info

Publication number
SMT201400029B
SMT201400029B SM201400029T SM201400029T SMT201400029B SM T201400029 B SMT201400029 B SM T201400029B SM 201400029 T SM201400029 T SM 201400029T SM 201400029 T SM201400029 T SM 201400029T SM T201400029 B SMT201400029 B SM T201400029B
Authority
SM
San Marino
Prior art keywords
acamprosate
baclofen
treatment
neurological disorders
disorders based
Prior art date
Application number
SM201400029T
Other languages
English (en)
Italian (it)
Inventor
Daniel Cohen
Lliya Chumakov
Serguei Nabirochkin
Emmanuel Vial
Mickael Guedj
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of SMT201400029B publication Critical patent/SMT201400029B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
SM201400029T 2011-03-01 2014-03-12 Terapia di disturbi neurologici a base di baclofene e acamprosato SMT201400029B (it)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP11305217 2011-03-01
US201161468658P 2011-03-29 2011-03-29
US201161493606P 2011-06-06 2011-06-06
EP11305687 2011-06-06
EP12708113.1A EP2560631B1 (fr) 2011-03-01 2012-03-01 Thérapie de troubles neurologiques à base de baclofène et d'acamprosate
PCT/EP2012/053570 WO2012117076A2 (fr) 2011-03-01 2012-03-01 Thérapie de troubles neurologiques à base de baclofène et d'acamprosate

Publications (1)

Publication Number Publication Date
SMT201400029B true SMT201400029B (it) 2014-07-07

Family

ID=46758335

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400029T SMT201400029B (it) 2011-03-01 2014-03-12 Terapia di disturbi neurologici a base di baclofene e acamprosato

Country Status (27)

Country Link
US (7) US9820978B2 (fr)
EP (5) EP2680835B1 (fr)
JP (2) JP5987008B2 (fr)
KR (2) KR101937782B1 (fr)
CN (2) CN105997969B (fr)
AU (2) AU2012222351B2 (fr)
BR (1) BR112013022112B1 (fr)
CA (1) CA2828765C (fr)
CY (3) CY1115074T1 (fr)
DK (3) DK2796132T3 (fr)
EA (2) EA023277B1 (fr)
ES (5) ES2665569T3 (fr)
HK (2) HK1182615A1 (fr)
HR (1) HRP20140131T1 (fr)
HU (1) HUE038653T2 (fr)
IL (2) IL228177B (fr)
LT (2) LT2727588T (fr)
MX (1) MX340568B (fr)
PL (3) PL2796132T3 (fr)
PT (1) PT2560631E (fr)
RS (3) RS58114B1 (fr)
SG (2) SG192968A1 (fr)
SI (3) SI2727588T1 (fr)
SM (1) SMT201400029B (fr)
TR (1) TR201809351T4 (fr)
WO (2) WO2012117076A2 (fr)
ZA (1) ZA201306039B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (fr) 2007-11-30 2009-06-03 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie de Charcot-Marie-Tooth
EP2135607A1 (fr) 2008-06-18 2009-12-23 Pharnext Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés
EP2263665A1 (fr) 2009-06-02 2010-12-22 Pharnext Nouvelles compositions pour traiter le CMT et troubles associés
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (fr) 2009-11-03 2011-05-18 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie d'Alzheimer
US9867837B2 (en) * 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
EP2705842A1 (fr) * 2012-09-05 2014-03-12 Pharnext Approches thérapeutiques pour le traitement de la maladie de Parkinson
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
CN104487064B (zh) * 2012-03-01 2018-01-26 法耐斯特公司 用于治疗肌萎缩性侧索硬化症的新组合物
CN105997969B (zh) 2011-03-01 2022-03-25 法耐斯特公司 基于巴氯芬和阿坎酸的神经性障碍疗法
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
GB2565939A (en) 2012-02-10 2019-02-27 Rational Intellectual Holdings Ltd Method and system for operating instances of a game
MX2014010481A (es) * 2012-03-01 2015-03-20 Pharnext Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
EA031331B9 (ru) * 2012-03-01 2019-02-28 Фарнекст Комбинация акампросата, баклофена и рилузола для лечения амиотрофического бокового склероза и родственного заболевания
ES2729208T3 (es) * 2012-07-18 2019-10-30 Pharnext Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
EP2705841A1 (fr) * 2012-09-05 2014-03-12 Pharnext Combinaisons des agents nootropiques destinées au traitement des dysfonctionnements cognitifs
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
SI3003268T1 (sl) 2013-06-05 2019-01-31 Pharnext Stabilne oralne raztopine za kombinirane API
CN105658238B (zh) * 2013-06-19 2019-07-12 索姆创新生物技术公司 用于在预防和/或治疗多动性运动障碍中使用的治疗剂
KR102206745B1 (ko) * 2013-07-12 2021-02-03 경상대학교산학협력단 안토시아닌 및 gabab 수용체 작용제를 유효성분으로 포함하는 신경질환 치료제
WO2015023830A1 (fr) 2013-08-14 2015-02-19 Stc.Unm Traitement et prévention d'un accident vasculaire cérébral et d'autres troubles neurologiques
EP3062782A1 (fr) * 2013-10-30 2016-09-07 Pharnext Compositions, procédés et utilisations pour le traitements de diabète et d'états associés en régulant le niveau de glycémie
JP6619744B2 (ja) * 2014-02-11 2019-12-11 ファーネクストＰｈａｒｎｅｘｔ 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用
KR102580378B1 (ko) * 2014-11-21 2023-09-19 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 릴루졸의 설하 제제
EP3291800A4 (fr) 2015-05-04 2018-09-26 Confluence Pharmaceuticals, LLC Formulations d'acamprosate à pulvériser
EP3156050A1 (fr) * 2015-10-16 2017-04-19 Universitat Autònoma De Barcelona Nouvelles thérapies combinées pour le traitement de lésions neurologiques
WO2017115873A1 (fr) 2015-12-29 2017-07-06 国立大学法人京都大学 Agent pour la prévention et/ou le traitement de la maladie d'alzheimer
AU2017216288B2 (en) * 2016-02-05 2022-06-02 Pharnext Novel combinatorial therapies of neurological disorders
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
AU2018258970B2 (en) * 2017-04-24 2021-07-15 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
WO2018213589A1 (fr) * 2017-05-17 2018-11-22 Confluence Pharmaceuticals, Llc Formulations d'homotaurines et de leurs sels
US11878001B2 (en) 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
WO2019145523A1 (fr) 2018-01-29 2019-08-01 Pharnext Thérapie de la maladie d'alzheimer à base de baclofène et d'acamprosate chez des patients ayant perdu la sensibilité à une thérapie par un inhibiteur de l'acétylcholinestérase
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2023154794A1 (fr) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Repositionnement de médicament pour le traitement différé d'un accident vasculaire cérébral ischémique
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6573251B2 (en) 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
AU3173301A (en) 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
OA12983A (en) 2001-07-19 2006-10-13 Pharmacia Corp Combination of an aldosterone receptor antagonist and an HMG COA reductase inhibitor.
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
KR20040091141A (ko) 2002-03-18 2004-10-27 파마시아 코포레이션 알도스테론 수용체 길항물질 및 니코틴산 또는 니코틴산유도체의 혼합물
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
EP1563846B1 (fr) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Promoteurs de production de facteurs de reparation endogenes
MXPA06001876A (es) 2003-08-20 2006-05-17 Xenoport Inc Prodrogas de aciloxialquil carbamato, metodos de sintesis y uso.
US7227028B2 (en) 2003-12-30 2007-06-05 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
JP4855268B2 (ja) 2004-11-30 2012-01-18 アンジェスＭｇ株式会社 アルツハイマー治療剤
US20080188510A1 (en) 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
AU2007269090A1 (en) 2006-07-06 2008-01-10 Roskamp Research Llc Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
CA2674610C (fr) 2007-01-11 2013-06-18 Xenoport, Inc. Formes galeniques orales a liberation prolongee d'un promedicament de r-baclofene et procedes de traitement
US20100298375A1 (en) 2007-05-22 2010-11-25 Heii Arai medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
WO2009033079A1 (fr) 2007-09-07 2009-03-12 Xenoport, Inc. Promédicaments de libération de cyclisation d'ester de néopentyle sulfonyle d'ester d'acide pantoïque masqués extérieurement, leurs compositions et procédés d'utilisation
US7994218B2 (en) 2007-09-07 2011-08-09 Xenoport, Inc. Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (fr) 2007-10-15 2009-04-23 Xenoport, Inc. Promédicaments de l'acamprosate à libération par cyclisation de néopentylsulfonylester à masquage interne, leurs compositions et procédés d'utilisation
TW200936123A (en) * 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2009096985A1 (fr) 2008-02-01 2009-08-06 Xenoport, Inc. Formes posologiques orales particulaires à libération soustenue de promédicaments de (r)-baclofène et procédés de traitement correspondants
KR101660401B1 (ko) * 2008-04-29 2016-09-27 파넥스트 신생혈관형성증 조절을 통한 알츠하이머 질환 및 관련 장애의 치료를 위한 신규 치료학적 접근법
ES2410930T3 (es) 2008-04-29 2013-07-03 Pharnext Nuevos enfoques terapéuticos para tratar la enfermedad de alzheimer y trastornos relacionados mediante la modulación de la respuesta de estrés celular
WO2009133128A1 (fr) * 2008-04-29 2009-11-05 Pharnext Compositions combinées destinées à traiter la maladie d’alzheimer et les troubles associés, au moyen de zonisamide et d’acamprosate
EP2135607A1 (fr) 2008-06-18 2009-12-23 Pharnext Combinaison de pilocarpine et methimazol pour le traitement de la maladie de Charcot-MarieTooth et des troubles associés
WO2010061931A1 (fr) 2008-11-27 2010-06-03 国立大学法人香川大学 Dérivé de purine cyclobutylique, agent favorisant l'angiogenèse, agent favorisant la luménisation, agent favorisant la croissance des neurocytes et médicament
EP2378883B1 (fr) * 2008-12-04 2015-12-23 Intec Pharma Ltd. Système d'administration de médicament à rétention gastrique pour le zaleplon
EP2403486A1 (fr) 2009-03-03 2012-01-11 XenoPort, Inc. Formes posologiques orales à libération entretenue d'un promédicament de r-baclofène
WO2010120370A2 (fr) 2009-04-17 2010-10-21 Xenoport, Inc. Dérivés d'acide gamma-aminobutyrique comme ligands des récepteurs gabab
EP2263665A1 (fr) 2009-06-02 2010-12-22 Pharnext Nouvelles compositions pour traiter le CMT et troubles associés
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2322163A1 (fr) 2009-11-03 2011-05-18 Pharnext Nouvelles approches thérapeutiques pour traiter la maladie d'Alzheimer
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
CN105997969B (zh) 2011-03-01 2022-03-25 法耐斯特公司 基于巴氯芬和阿坎酸的神经性障碍疗法
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders

Also Published As

Publication number Publication date
CN105997969B (zh) 2022-03-25
EA201300974A1 (ru) 2014-01-30
US20130090307A1 (en) 2013-04-11
EP2560631B1 (fr) 2014-01-15
US20140378440A1 (en) 2014-12-25
HUE038653T2 (hu) 2018-11-28
ZA201306039B (en) 2014-10-29
NZ614184A (en) 2015-08-28
AU2012222351B2 (en) 2017-05-18
AU2017210501A1 (en) 2017-08-17
US20200085790A1 (en) 2020-03-19
EA201891833A1 (ru) 2019-01-31
JP2017193562A (ja) 2017-10-26
EP2796132B1 (fr) 2018-05-02
DK2727588T3 (en) 2018-12-10
PT2560631E (pt) 2014-02-24
DK2560631T3 (da) 2014-02-10
WO2012117076A2 (fr) 2012-09-07
LT2727588T (lt) 2019-01-25
IL228177B (en) 2018-01-31
EA023277B1 (ru) 2016-05-31
CY1120369T1 (el) 2019-07-10
CA2828765C (fr) 2019-07-30
MX340568B (es) 2016-07-14
US9636316B2 (en) 2017-05-02
JP6416328B2 (ja) 2018-10-31
JP5987008B2 (ja) 2016-09-06
KR20180043844A (ko) 2018-04-30
CN103596562B (zh) 2016-06-01
EP3332781A1 (fr) 2018-06-13
ES2845204T3 (es) 2021-07-26
RS57426B1 (sr) 2018-09-28
CY1120925T1 (el) 2019-12-11
LT2796132T (lt) 2018-10-10
PL2796132T3 (pl) 2018-10-31
PL2560631T3 (pl) 2014-06-30
EP2796132A1 (fr) 2014-10-29
SI2796132T1 (sl) 2018-09-28
PL2727588T3 (pl) 2019-04-30
WO2012117075A2 (fr) 2012-09-07
IL261725A (en) 2018-10-31
AU2012222351A1 (en) 2013-08-29
US8865769B2 (en) 2014-10-21
BR112013022112A2 (pt) 2018-06-26
EP2727588A1 (fr) 2014-05-07
US9144558B2 (en) 2015-09-29
SG10201610587SA (en) 2017-02-27
RS58114B1 (sr) 2019-02-28
ES2678794T3 (es) 2018-08-17
US8741886B2 (en) 2014-06-03
SI2727588T1 (sl) 2019-03-29
AU2017210501B2 (en) 2018-11-01
WO2012117076A3 (fr) 2012-10-26
US20130085122A1 (en) 2013-04-04
TR201809351T4 (tr) 2018-07-23
RS53227B (en) 2014-08-29
ES2698927T3 (es) 2019-02-06
CN103596562A (zh) 2014-02-19
EP2727588B1 (fr) 2018-08-29
KR101918745B1 (ko) 2018-11-15
US20140080873A1 (en) 2014-03-20
HRP20140131T1 (hr) 2014-05-09
CY1115074T1 (el) 2016-12-14
KR101937782B1 (ko) 2019-01-11
SI2560631T1 (sl) 2014-06-30
EP2680835B1 (fr) 2018-02-07
MX2013010043A (es) 2014-02-11
HK1182615A1 (en) 2013-12-06
BR112013022112B1 (pt) 2021-09-28
CA2828765A1 (fr) 2012-09-07
JP2014510069A (ja) 2014-04-24
EP2560631A2 (fr) 2013-02-27
KR20140038378A (ko) 2014-03-28
US9820978B2 (en) 2017-11-21
SG192968A1 (en) 2013-09-30
ES2450074T3 (es) 2014-03-21
ES2665569T3 (es) 2018-04-26
DK2796132T3 (en) 2018-07-23
EP2680835A2 (fr) 2014-01-08
WO2012117075A3 (fr) 2012-12-13
CN105997969A (zh) 2016-10-12
HK1203158A1 (en) 2015-10-23
US20160000736A1 (en) 2016-01-07
US20170231958A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
SMT201400029B (it) Terapia di disturbi neurologici a base di baclofene e acamprosato
DK2709667T3 (da) Bio-orthogonal lægemiddelaktivering
DK2701695T3 (da) Neurodegenerative lidelser og muskelsygdomme, der involverer polyumættede fedtsyrer
EP2621499A4 (fr) Méthodes de traitement de maladies allergiques
HK1201438A1 (en) Treatment of ocular disease
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
IL225896A0 (en) Treatment of mecp-2 related disorders
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
IL230960A0 (en) A device for the treatment of eye disease
BR112013031702A2 (pt) 1-piperazino-3-fenil indanos deuterados para o tratamento de esquizofrenia
BR112014004418A2 (pt) tratamento de sintomas associados à gastroparesia feminina
ITMI20120445A1 (it) Dispositivo e procedimento per la produzione di spazzole circolari
DK2673363T3 (da) Behandling af angiogenesesygdomme
EP2681209A4 (fr) Composés et méthodes de traitement de la douleur et d&#39;autres troubles
IL230959B (en) A device for the treatment of eye disease
DK2694056T3 (da) Terapeutisk behandling
EP2800554A4 (fr) Procédés pour le traitement de la sclérose en plaques et d&#39;autres troubles de démyélinisation
GB201107467D0 (en) Novel treatment of pain
HRP20181945T1 (hr) Liječenje neuroloških poremećaja na bazi baklofena i akamprozata
IT1406405B1 (it) Molecole peptidiche per il trattamento di patologie mitocondriali
GB201118065D0 (en) Treatment of movement disorders
GB201101773D0 (en) Treatment of inflammatory disorders
GB201102366D0 (en) Methods and reagents for the treatment of allergic disorders
FI20115905A0 (fi) Käsittelyjärjestely